The article is a first-person narrative of the author's experience at a massage parlor in Yogyakarta, Indonesia. The author humorously describes the intense and painful massage session he underwent, which included a traditional Javanese full-body massage. The masseuse's techniques are depicted as surprisingly vigorous and at times uncomfortable, involving deep manipulation of muscles and joints. Despite the pain, the author hints at an underlying belief that the massage would ultimately be beneficial. The article concludes with a playful reference to the massage parlor's window signs stating 'No sex. No drugs,' with the author jokingly suggesting that a pain reliever might have been a good idea before the session.

The article addresses a false report claiming that the European Union is seeking to remove Cambodia from the United Nations. It clarifies that the European Parliament did not pass a resolution to this effect on September 13, nor was it discussed. The resolution in question actually calls for sanctions against Cambodia for human rights violations and a review of its involvement in a preferential trade deal. Cambodian officials have dismissed the idea of being ejected from the UN as impossible, citing support from Russia and China in the UN Security Council. The article also mentions the European Parliament's resolution urging the Cambodian government to renew an agreement with the High Commissioner for Human Rights and to address human rights concerns. The resolution is not binding but serves as a call to action for other EU bodies. Prime Minister Hun Sen has announced his upcoming visit to the UN General Assembly, where he will meet with various officials.

The letter to the editor discusses concerns about the substantial excess expenditures for Lipitor despite the availability of generic atorvastatin. It highlights the difficulty in assessing the validity of conclusions due to proprietary pharmaceutical industry rebates.

The use of gabapentinoids, specifically gabapentin and pregabalin, significantly increased in the United States from 2002 to 2015, with gabapentin being the predominantly used medication. The increase in use was particularly notable among older adults, individuals with diabetes, and those with multiple comorbidities or opioid/benzodiazepine prescriptions. The study highlights concerns about the safety and efficacy of gabapentinoids, especially given their off-label use and potential risks when combined with opioids. The findings suggest a need for caution in prescribing these medications, particularly for long-term opioid users.

The study estimates potential savings from therapeutic substitution, where branded drugs are replaced with generics within the same class. Using data from the Medical Expenditure Panel Survey (2010-2012), the study found that $73 billion in excess expenditure was due to branded drug overuse, with $24.6 billion in out-of-pocket costs. The analysis highlights significant savings across various drug classes, including statins and atypical antipsychotics. Despite opposition from physician organizations, therapeutic substitution could reduce drug costs without compromising care quality.